Growth Metrics

Ligand Pharmaceuticals (LGNDZ) Net Income towards Common Stockholders (2018 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Net Income towards Common Stockholders for 15 consecutive years, with $44.8 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 244.06% to $44.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124.5 million through Dec 2025, up 500.32% year-over-year, with the annual reading at $124.5 million for FY2025, 3186.63% up from the prior year.
  • Net Income towards Common Stockholders hit $44.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $117.3 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $117.3 million in Q3 2025 to a low of -$42.5 million in Q1 2025.
  • Historically, Net Income towards Common Stockholders has averaged $3.2 million across 5 years, with a median of -$3.8 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 136.03% in 2022 and later skyrocketed 244.06% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$2.2 million in 2021, then crashed by 32.75% to -$3.0 million in 2022, then surged by 43.58% to -$1.7 million in 2023, then crashed by 1767.15% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for LGNDZ at $44.8 million in Q4 2025, $117.3 million in Q3 2025, and $4.8 million in Q2 2025.